a significant increase of plasma Glu and a significant reduction of plasma GABA/Glu ratio were observed The ratio returned to the control level at week 6 even though concentrations of GABA and Glu were still distant from normal After the Bonferroni correction, partial correlation analyses showed that plasma GABA and GABA/Glu ratio were positively correlated with the close of risperidone and plasma concentration of 9-hydroxyrisperidone The reduction of
plasma GABA/Glu ratio was positively correlated with the improvement of activation symptom cluster.
Conclusions: The elevated plasma Selleckchem PND-1186 GABA/Glu ratio reinforces the Idea of an abnormal GABA-Glu interaction in schizophrenia The ratio may be a good peripheral
state-like marker in schizophrenia research (C) 2010 Elsevier Inc All rights reserved”
“Introduction Some studies have found that antidepressants increase serum brain-derived neurotrophic factor (BDNF) levels in patients with major depression and the expression KPT-8602 purchase of BDNF mRNA in limbic structures of rats
Objectives. This study addressed whether the SSRI escitalopram increases serum BDNF levels in subjects with PTSD and whether BDNF levels are associated with treatment response
Methods Medically Calpain healthy male subjects (N= 16) with chronic PTSD completed a 12 week open-label trial of flexible dose (5-20 mg/day) escitalopram monotherapy BDNF levels were obtained at baseline, and at weeks 4,8 and 12
Results PTSD symptoms significantly declined over the course of the 12 week escitalopram treatment Despite a substantial improvement
in PTSD symptoms, there was virtually no change in BDNF levels over time Nevertheless, mean BDNF levels across the trial were strongly correlated with the slope of PTSD symptoms over the 12 weeks (r = 0 58. p = 0.018). Lower mean BDNF was associated with a greater decrease in PTSD symptoms over the course of the trial
Conclusions PTSD subjects with low BDNF levels demonstrated the largest treatment response from an agent with putative neurotrophic effects (C) 2010 Elsevier Inc All rights reseived”
“BACKGROUND
Diabetes is a risk factor for dementia. It is unknown whether higher glucose levels increase the risk of dementia in people without diabetes.
METHODS
We used 35,264 clinical measurements of glucose levels and 10,208 measurements of glycated hemoglobin levels from 2067 participants without dementia to examine the relationship between glucose levels and the risk of dementia.